Table 1.
Characteristics of 3616 men with a biopsy stratified to prostate cancer outcome from the European Randomized Study of Screening for Prostate Cancer (ERSPC).
| Characteristics | No PCa n = 2731 (75%) |
Indolent PCa (GS 3 + 3) n = 572 (16%) |
PCa GS ≥3 + 4 n = 313 (9%) |
|---|---|---|---|
| Age, years, median (IQR) | 66 (60–70) | 67 (61–70) | 68 (64–71) |
| PSA, ng/mL, median (IQR) | 4.0 (2.5–5.7) | 5.1 (3.7–7.4) | 7.8 (4.8–16.0) |
| %FreePSA | 0.22 (0.17–0.28) | 0.17 (0.12–0.24) | 0.12 (0.08–0.17) |
| Prostate volume, mL, median (IQR) | 43 (33–57) | 37 (29–50) | 37 (29–47) |
| Abnormal DRE, n (%) | 836 (31) | 236 (41) | 207 (66) |
| Abnormal TRUS, n (%) | 795 (29) | 226 (40) | 208 (66) |
| Positive family history, n (%) | 210 (8) | 64 (11) | 30 (10) |
| IPSS, median (IQR) | 5 (2–11) | 4 (1–9) | 4 (1–10) |
PCa = prostate cancer, GS = Gleason Score, DRE = digital rectal exam, TRUS = transrectal ultrasound, PSA = prostate-specific antigen, IQR = interquartile range, IPSS = International Prostate Symptom Score.